Meeting NewsVideo

VIDEO: CAR T-cell therapy has ‘incredible potency’ in chronic lymphocytic leukemia

NEW YORK — In this video commentary from HemOnc Today New York, co-program chair David L. Porter, MD, discussed the use of chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

CAR T cells have “incredibly potency” in CLL, said Porter, director of the cell therapy and transplant program at the University of Pennsylvania.

More than 50% of patients achieve a response, and 25% to 30% of patients achieve complete remission.

CAR T cells can persist for long periods of time in the blood, which may prevent relapse. Some data shows persistence for more than 5 years.

Toxicities, including cytokine release syndrome, appear to be manageable for the majority of patients.

“Overall, CAR T cells are going to be an important part of developing therapies for CLL and other B cell malignancies,” Porter said.

 

Disclosure: Porter reports intellectual property interests with Novartis.

NEW YORK — In this video commentary from HemOnc Today New York, co-program chair David L. Porter, MD, discussed the use of chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

CAR T cells have “incredibly potency” in CLL, said Porter, director of the cell therapy and transplant program at the University of Pennsylvania.

More than 50% of patients achieve a response, and 25% to 30% of patients achieve complete remission.

CAR T cells can persist for long periods of time in the blood, which may prevent relapse. Some data shows persistence for more than 5 years.

Toxicities, including cytokine release syndrome, appear to be manageable for the majority of patients.

“Overall, CAR T cells are going to be an important part of developing therapies for CLL and other B cell malignancies,” Porter said.

 

Disclosure: Porter reports intellectual property interests with Novartis.

    See more from HemOnc Today New York